Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Strong vaccine responses during chemotherapy are associated with prolonged cancer survival.
Melief CJM, Welters MJP, Vergote I, Kroep JR, Kenter GG, Ottevanger PB, Tjalma WAA, Denys H, van Poelgeest MIE, Nijman HW, Reyners AKL, Velu T, Goffin F, Lalisang RI, Loof NM, Boekestijn S, Krebber WJ, Hooftman L, Visscher S, Blumenstein BA, Stead RB, Gerritsen W, van der Burg SH. Melief CJM, et al. Among authors: nijman hw. Sci Transl Med. 2020 Mar 18;12(535):eaaz8235. doi: 10.1126/scitranslmed.aaz8235. Sci Transl Med. 2020. PMID: 32188726 Free article.
Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.
Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller RP, Franken KL, Nijman HW, Ossendorp F, Van Der Burg SH, Offringa R, Melief CJ. Zwaveling S, et al. Among authors: nijman hw. Cancer Res. 2002 Nov 1;62(21):6187-93. Cancer Res. 2002. PMID: 12414646
Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia.
van Poelgeest MI, Nijhuis ER, Kwappenberg KM, Hamming IE, Wouter Drijfhout J, Fleuren GJ, van der Zee AG, Melief CJ, Kenter GG, Nijman HW, Offringa R, van der Burg SH. van Poelgeest MI, et al. Among authors: nijman hw. Int J Cancer. 2006 Feb 1;118(3):675-83. doi: 10.1002/ijc.21394. Int J Cancer. 2006. PMID: 16108057 Free article.
Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.
Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, Valentijn AR, Oostendorp J, Fathers LM, Nijman HW, Drijfhout JW, van de Velde CJ, Melief CJ, van der Burg SH. Speetjens FM, et al. Among authors: nijman hw. Clin Cancer Res. 2009 Feb 1;15(3):1086-95. doi: 10.1158/1078-0432.CCR-08-2227. Clin Cancer Res. 2009. PMID: 19188184 Free article. Clinical Trial.
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.
Leffers N, Lambeck AJ, Gooden MJ, Hoogeboom BN, Wolf R, Hamming IE, Hepkema BG, Willemse PH, Molmans BH, Hollema H, Drijfhout JW, Sluiter WJ, Valentijn AR, Fathers LM, Oostendorp J, van der Zee AG, Melief CJ, van der Burg SH, Daemen T, Nijman HW. Leffers N, et al. Among authors: nijman hw. Int J Cancer. 2009 Nov 1;125(9):2104-13. doi: 10.1002/ijc.24597. Int J Cancer. 2009. PMID: 19621448 Free article. Clinical Trial.
Vaccine-based clinical trials in ovarian cancer.
Leffers N, Daemen T, Boezen HM, Melief KJ, Nijman HW. Leffers N, et al. Among authors: nijman hw. Expert Rev Vaccines. 2011 Jun;10(6):775-84. doi: 10.1586/erv.11.42. Expert Rev Vaccines. 2011. PMID: 21692699 Review.
202 results